Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: tonyt who wrote (1251)	3/4/1998 11:37:00 PM
From: D.Right	Read Replies (3) \| Respond to of 2173

Facts about AMLN Bad ones: 1.JNJ did pull out. 2.AMLN is short on cash. 3.AMLN has to slow down on other development. 4.It is a long time to 2000. 5.Stock price is so low for people bought before (I am one of the stupid ones). Good ones: 1.Pramlintide is the only one shown by trial III to help type I patients other than insulin. 2.AMLN does have all the right to pramlintide again. 3.Pramlintide did get statistic significant weight reduction of up to seven pounds in type II patients, which no other drug can claim. 4.This is a rumor as I didn't hear it myself. 75% trial patients are sill on it. 5.European file will be in 1999 for type I (Henry, you are a fan for off-lable use for LGND's drug only, I guess). 6.1999 is one year earlier than 2000. 7.December is 9 months away. 8.Stock price is so low for people just bought. If I missed important facts, let me know. D.Right